Market Overview:
The global recombinant human interleukin market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for biologics and growing investments in R&D by pharmaceutical companies. The recombinant human interleukin market is segmented on the basis of type, application and region. On the basis of type, the market is segmented into IL-1, IL-2, IL-10 and others. The IL-1 segment is expected to account for the largest share of the global recombinant human interleukin market in 2018 owing to its high usage in medication and scientific research applications. On the basis of application,the market is divided into medication and scientific research applications.
Product Definition:
Interleukin-2 (IL-2) is a cytokine that is produced by T cells and natural killer cells. IL-2 signals the body to produce more white blood cells, which helps the immune system fight infection and disease. Recombinant human interleukin-2 (rhIL-2) is a manmade version of IL-2 that is used to treat cancer. It works by stimulating the growth of T cells and natural killer cells, which can help destroy cancerous tumors.
IL-1:
IL-1 is a cytokine that belongs to the interleukin family. Interleukins are heterogeneous group of proteins consisting of several subtypes produced by cells in response to foreign substances such as bacteria, viruses, and tumor cells. IL-1 has two main forms: Type I and Type II.
IL-2:
IL-2 is a type of interleukin. Interleukins are protein molecules that are produced by certain cells in the immune system and some non-immune cells such as fibroblasts. There are multiple types of interleukins, each with a specific function during infection or inflammation.
IL-1 - Activates the immune system to respond to an infection/inflammatory stimulus IL-4 - Helps stimulate B cell production.
Application Insights:
IL-1 application segment led the global market in 2017. This is attributed to its wide usage as a cytokine therapy for various diseases, such as rheumatoid arthritis, osteoarthritis, and inflammatory bowel disease. Furthermore, it is also used in the treatment of chronic pain due to neurogenic and nociceptive pains. The growing use of recombinant human IL-1 for medication applications will drive growth during the forecast period.
The scientific research segment is expected to witness lucrative growth over the forecast period owing to increasing R&D activities pertaining recombinant human interleukin for vaccine development against infectious diseases such as HIV/AIDS and tuberculosis among others. Moreover, increasing R&D investments by companies operating in this sector will further boost product demand over the coming years.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biotechnology and pharmaceutical companies, which are engaged in developing and commercializing products based on rHIL-1 proteins, is one of the major factors contributing to this dominance. Furthermore, increasing government initiatives for funding research activities pertaining to interleukin are also expected to drive regional growth over the forecast period.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure by governments as well as private sectors coupled with growing awareness regarding advanced treatment options for various diseases including cancer and diabetes.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. Recombinant human interleukin helps in the treatment of various chronic diseases such as cancer, rheumatoid arthritis, and Crohn’s disease, thereby driving its demand.
- Technological advancements: The recombinant human interleukin market is witnessing rapid technological advancements, which are helping to improve the quality and efficacy of products in this market. This is resulting in an increase in their demand among consumers worldwide.
- Rising awareness about benefits offered by recombinant human interleukins: There has been a rise in awareness about the benefits offered by recombinant human interleukins among consumers across the globe in recent years. This is helping to drive growth in this market significantly.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Human Interleukin Market Research Report
By Type
IL-1, IL-2, IL-10, Others
By Application
Medication, Scientific Research
By Companies
Qilu Pharmaceutical, Hangzhou Jiuyuan, Merck and Co, Novartis Pharma, Abnova, Advanced Biotechnologies Inc, Cayman Chemical, Cell Signaling Technology, Thermo Fisher, Qilu Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
150
Number of Tables & Figures
105
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Human Interleukin Market Report Segments:
The global Recombinant Human Interleukin market is segmented on the basis of:
Types
IL-1, IL-2, IL-10, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Medication, Scientific Research
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Qilu Pharmaceutical
- Hangzhou Jiuyuan
- Merck and Co
- Novartis Pharma
- Abnova
- Advanced Biotechnologies Inc
- Cayman Chemical
- Cell Signaling Technology
- Thermo Fisher
- Qilu Pharmaceutical
Highlights of The Recombinant Human Interleukin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- IL-1
- IL-2
- IL-10
- Others
- By Application:
- Medication
- Scientific Research
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Human Interleukin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant human interleukin (rhIL-6) is a protein that is produced by recombinant DNA technology. It is a type I cytokine, which means that it helps the body to fight against infections. rhIL-6 can help to improve the symptoms of conditions such as rheumatoid arthritis, Crohn's disease, and multiple sclerosis.
Some of the major players in the recombinant human interleukin market are Qilu Pharmaceutical, Hangzhou Jiuyuan, Merck and Co, Novartis Pharma, Abnova, Advanced Biotechnologies Inc, Cayman Chemical, Cell Signaling Technology, Thermo Fisher, Qilu Pharmaceutical.
The recombinant human interleukin market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Human Interleukin Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Human Interleukin Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Human Interleukin Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Human Interleukin Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Human Interleukin Market Size & Forecast, 2018-2028
4.5.1 Recombinant Human Interleukin Market Size and Y-o-Y Growth
4.5.2 Recombinant Human Interleukin Market Absolute $ Opportunity
Chapter 5 Global Recombinant Human Interleukin Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Recombinant Human Interleukin Market Size Forecast by Type
5.2.1 IL-1
5.2.2 IL-2
5.2.3 IL-10
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Recombinant Human Interleukin Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Recombinant Human Interleukin Market Size Forecast by Applications
6.2.1 Medication
6.2.2 Scientific Research
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Human Interleukin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Human Interleukin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Recombinant Human Interleukin Analysis and Forecast
9.1 Introduction
9.2 North America Recombinant Human Interleukin Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Recombinant Human Interleukin Market Size Forecast by Type
9.6.1 IL-1
9.6.2 IL-2
9.6.3 IL-10
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Recombinant Human Interleukin Market Size Forecast by Applications
9.10.1 Medication
9.10.2 Scientific Research
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Recombinant Human Interleukin Analysis and Forecast
10.1 Introduction
10.2 Europe Recombinant Human Interleukin Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Recombinant Human Interleukin Market Size Forecast by Type
10.6.1 IL-1
10.6.2 IL-2
10.6.3 IL-10
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Recombinant Human Interleukin Market Size Forecast by Applications
10.10.1 Medication
10.10.2 Scientific Research
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Recombinant Human Interleukin Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Recombinant Human Interleukin Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Recombinant Human Interleukin Market Size Forecast by Type
11.6.1 IL-1
11.6.2 IL-2
11.6.3 IL-10
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Recombinant Human Interleukin Market Size Forecast by Applications
11.10.1 Medication
11.10.2 Scientific Research
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Recombinant Human Interleukin Analysis and Forecast
12.1 Introduction
12.2 Latin America Recombinant Human Interleukin Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Recombinant Human Interleukin Market Size Forecast by Type
12.6.1 IL-1
12.6.2 IL-2
12.6.3 IL-10
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Recombinant Human Interleukin Market Size Forecast by Applications
12.10.1 Medication
12.10.2 Scientific Research
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Recombinant Human Interleukin Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Recombinant Human Interleukin Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Recombinant Human Interleukin Market Size Forecast by Type
13.6.1 IL-1
13.6.2 IL-2
13.6.3 IL-10
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Recombinant Human Interleukin Market Size Forecast by Applications
13.10.1 Medication
13.10.2 Scientific Research
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Human Interleukin Market: Competitive Dashboard
14.2 Global Recombinant Human Interleukin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Qilu Pharmaceutical
14.3.2 Hangzhou Jiuyuan
14.3.3 Merck and Co
14.3.4 Novartis Pharma
14.3.5 Abnova
14.3.6 Advanced Biotechnologies Inc
14.3.7 Cayman Chemical
14.3.8 Cell Signaling Technology
14.3.9 Thermo Fisher
14.3.10 Qilu Pharmaceutical
